Enjoy complimentary customisation on priority with our Enterprise License!
The gastrointestinal stromal tumors therapeutics market size is forecast to increase by USD 525 million at a CAGR of 7.4% between 2024 and 2029.
Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The gastrointestinal stromal tumors therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
The oral segment is estimated to witness significant growth during the forecast period. Currently, the oral segment is dominating the global gastrointestinal stromal tumors therapeutics market, primarily due to the presence of large pharmaceutical companies such as Bayer, Novartis, and Pfizer with their specialty drugs for the treatment of the indication. Drugs such as STIVARGA by Bayer, GLEEVEC by Novartis, and SUTENT by Pfizer have gained popularity due to their ability to target multiple proteins in the body and inhibit the abnormal division of the cells in the body. For instance, GLEEVEC, the most popular drug for the treatment of gastrointestinal stromal tumors, has been designed to target multiple proteins such as c-kit and platelet-derived growth factor receptor alpha (PDGFRA).
The ease of administration is also increasing patient adherence to the treatment using these drugs, which will aid in the growth of the oral segment during the forecast period.However, the oral segment faces a heavy threat from the patent expiry of these major drugs. As these drugs have either lost most or all of the patents in the major markets, the oral segment is expected to witness a number of generic drugs entering the market. Despite the expected volume growth, the entry of generics is expected to cause value erosion owing to their low prices. This is expected to result in the oral segment losing some of its market share to the parenteral segment. However, the demand for these drugs is expected to remain higher than the generic drugs during the forecast period, which results in a partial offset of the damage caused by generics.
The parenteral route involves the administration of drugs into the body through subcutaneous, intravenous, and intramuscular routes. Currently, this segment has a few traditional chemotherapy drugs that are approved for the treatment of the indication. The share of the segment in the market remained very low for a long time due to the poor efficacy of traditional chemotherapies for the treatment of gastrointestinal stromal tumors. Patients do not always respond well to the treatment using chemotherapy, as it often fails to shrink the tumor completely. In some cases, the treatment using traditional chemotherapy drugs does not show any improvement in patients. As a result, traditional chemotherapy, which is often administered through the parenteral route, has remained a less preferred treatment option.
The Oral segment was valued at USD 707.40 million in 2019 and showed a gradual increase during the forecast period.
However, the market witnesses the presence of various companies that are developing novel drugs for administration through this route. Most of the drugs that are being developed in the late stages of the gastrointestinal stromal tumors pipeline are biologics. The parenteral route remains the most preferred route for biologics, as the administration through the oral route often results in the drug losing its efficacy. Various novel checkpoint inhibitors or targeted therapies, such as KEYTRUDA by Merck and OPDIVO by BMS, are being studied in the late stages of clinical trials for the treatment of this indication. For instance, KEYTRUDA is being studied in Phase III of clinical trials, while OPDIVO is being studied in Phase II of clinical trials for the treatment of gastrointestinal stromal tumors.
These drugs are expected to receive marketing approval during the forecast period and are expected to add significant value to the market growth owing to their high efficacy and demand. The popularity of these drugs for the treatment of various cancer indications has led them to receive blockbuster status, which is expected to attract a major share of patients to undergo treatment using these drugs during the forecast period. The pipeline for the indication also witnesses the presence of cancer vaccines in the early stages of clinical trials. For instance, Mendus is currently conducting studies on Intuvax, which is a novel cancer vaccine that is being studied in Phase I of clinical trials. The diagnostic process for GIST involves medical history, physical examination, and various tests such as CT scan, MRI, endoscopic ultrasonography, and biopsy, followed by immunohistochemistry and mitotic rate assessment.
Similarly, various other companies in the early stages of the pipeline are developing novel therapies that are administered through the parenteral route. Although these drugs are not expected to receive marketing approval from the US FDA and the EMA during the forecast period, these drugs are expected to add significant value to the growth of the parenteral segment. Owing to the advances in research and the expected launch of novel drugs during the forecast period, the parenteral segment is expected to witness an accelerating growth momentum and become the fastest-growing segment of the global gastrointestinal stromal tumors therapeutics market during the forecast period.
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
In the US, the gastrointestinal stromal tumors (GIST) therapeutics market is experiencing growth due to the large pharmaceutical market in North America. While surgery remains a prominent treatment option, there has been a rising adoption of therapeutics for managing GIST. Despite the approaching patent expiry of drugs like GLEEVEC, STIVARGA, and SUTENT, the market demand for these medications has remained relatively stable. Several companies are introducing generic versions of these drugs in the region. Patient advocacy groups and increased disease awareness have led to a greater focus on improving patient management and clinical outcomes. End-of-life care and palliative care are essential components of GIST treatment, with a growing emphasis on value-based healthcare.
Drug development in the GIST therapeutics market is ongoing, with a focus on precision oncology, targeted therapies, and combination therapies. Tyrosine kinase inhibitors, such as imatinib mesylate and sunitinib malate, continue to be key players in the market. Research funding, including foundation grants and government grants, is crucial for advancing the understanding of GIST and developing new treatments. Adverse events and drug interactions are significant concerns, necessitating rigorous clinical trials and patient education. Synergistic effects of combination therapies and radiation therapy are being explored to enhance treatment efficacy. Hospice care and pain management are essential aspects of GIST treatment, particularly during the end stages of the disease.
The market is expected to continue evolving, with a focus on personalized medicine and combination therapies to improve patient outcomes.
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The gastrointestinal stromal tumors therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the gastrointestinal stromal tumors therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, gastrointestinal stromal tumors therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AB Science SA - The company specializes in the development of gastrointestinal stromal tumors (GIST) therapeutics, featuring masitinib as a prominent solution.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The gastrointestinal stromal tumors (GIST) therapeutics market continues to evolve as new treatments and technologies emerge, addressing the complexities of managing this rare and often challenging disease. The ongoing unfolding of market activities is driven by a range of factors, including advancements in our understanding of the disease mechanism, the development of new therapeutic approaches, and the evolving landscape of healthcare delivery and reimbursement. Five-year survival rates for GIST patients have improved significantly in recent years, thanks to the availability of targeted therapies such as imatinib mesylate and sunitinib malate. However, these treatments come with their own challenges, including nausea and vomiting, adverse events, and the need for ongoing monitoring and management.
Research funding plays a critical role in advancing our understanding of GIST and developing new treatments. Biotech companies are at the forefront of this research, leveraging precision oncology and molecular diagnostics to develop targeted therapies and personalized treatment regimens. Value-based healthcare is also influencing the GIST therapeutics market, with a growing focus on clinical outcomes, patient education, and symptom management. Drug development is a complex and lengthy process, with various phases of clinical trials and regulatory approvals required before a new treatment can reach patients. The drug approval process involves close collaboration between regulatory agencies, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), and biotech companies.
Adverse events and drug interactions are closely monitored throughout the approval process to ensure patient safety. Medical devices and molecular diagnostics are also playing an increasingly important role in GIST management, from surgical interventions and pain management to disease burden assessment and targeted therapy resistance monitoring. The ongoing evolution of the GIST therapeutics market is shaped by a range of factors, from disease awareness and public education to synergistic effects of combination therapies and the role of checkpoint inhibitors in targeted therapy resistance. The market is expected to continue unfolding in the coming years, with a focus on improving patient outcomes, reducing disease burden, and enhancing quality of life for GIST patients. Additionally, research is ongoing for regenerative therapies, such as gene therapy, to ensure complete tumor remission. Genetic research reveals various genes linked to GIST progression.
The Gastrointestinal Stromal Tumors (GIST) Therapeutics Market is advancing with rigorous Phase I trials, evaluating safety and dosage parameters for novel treatments. Successful candidates progress to Phase II trials, where efficacy and side effects are assessed in a larger patient group. Later-stage Phase III trials focus on confirming effectiveness across diverse populations, ensuring robust clinical validation before regulatory submission. Achieving EMA approval is a crucial milestone, facilitating wider access to innovative therapies in Europe. Optimized treatment regimens are key to improving patient outcomes, integrating targeted therapies, immunotherapy, and precision medicine approaches.
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Gastrointestinal Stromal Tumors Therapeutics Market insights. See full methodology.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
214 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.4% |
|
Market growth 2025-2029 |
USD 525 million |
|
Market structure |
Fragmented |
|
YoY growth 2024-2025(%) |
6.8 |
|
Key countries |
US, Germany, China, Canada, France, Japan, UK, Italy, India, and Mexico |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
We can help! Our analysts can customize this gastrointestinal stromal tumors therapeutics market research report to meet your requirements.
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Route of Administration
9 Market Segmentation by Distribution Channel
10 Market Segmentation by Therapy
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
